Cantor Fitzgerald sees AVITA's superior growth and high gross margins as reasons for a premium. The firm also sees potential in Pacific Biosciences and AxoGen, and expects positive share price appreciation for Exagen and NeuroPace. A significant catalyst for Nyxoah's stock is anticipated with upcoming DREAM study data.
AxoGen's EBIT loss and debt levels could strain its balance sheet despite its US$368.0m market cap. While revenue is growing, its financial performance is considered slow.
CEO of Axogen, Karen Zaderej is excited for Kathy Weiler to use her vast commercial knowledge to aid the company's goal of becoming cash flow positive. Weiler herself is equally fired up to be able to aid in Axogen's commercial success.
The recent insider selling, despite small insider buying in AxoGen, raises concerns on the stock. Despite the reasonably high level of insider ownership, the history of sales makes the investment prospect less attractive in the immediate term.
Gainers: In reaction to earnings/guidance: •$Silvergate Capital(SI.US)$+10.7% (Silvergate (ticker: SI) notched net income of $38.6 million in the June quarter, delivering earnings per share (EPS) of $1.13.) •$AxoGen(AXGN.US)$+3.3% (guides Q2 revs above consensus; also makes changes to its commercial organization), •$诺华制药(NVS.US)$+ 3% (The Swiss pharmaceutical company on Tuesday posted net profit of $1.69 billion, down from...
Gainers: •$Intercept Pharmaceuticals(ICPT.US)$+25.7% (to sell license to commercialize Ocaliva outside the US to Advanz Pharma for upfront payment of $405 mln) •$美国雅保(ALB.US)$+13.9% (earnings reports) •$Booking Holdings(BKNG.US)$+10% (Booking Holdings' Outlook for a 'Busy' summer season drives the stock sharply higher) •$AxoGen(AXGN.US)$+9% (reports top-line results from RECON study of Avance Nerge Graft) •$积云媒体(CMLS.US)$+7.2% (an...
15
1
8
举报
RDK79 :
Guess recent airline headlines didn’t help pump Spirit
AxoGen股票讨论区
looks like more 💰flow and narrower loss this years looks interesting here
In reaction to earnings/guidance:
• $Silvergate Capital(SI.US)$ +10.7% (Silvergate (ticker: SI) notched net income of $38.6 million in the June quarter, delivering earnings per share (EPS) of $1.13.)
• $AxoGen(AXGN.US)$ +3.3% (guides Q2 revs above consensus; also makes changes to its commercial organization),
• $诺华制药(NVS.US)$ + 3% (The Swiss pharmaceutical company on Tuesday posted net profit of $1.69 billion, down from...
• $Intercept Pharmaceuticals(ICPT.US)$ +25.7% (to sell license to commercialize Ocaliva outside the US to Advanz Pharma for upfront payment of $405 mln)
• $美国雅保(ALB.US)$ +13.9% (earnings reports)
• $Booking Holdings(BKNG.US)$ +10% (Booking Holdings' Outlook for a 'Busy' summer season drives the stock sharply higher)
• $AxoGen(AXGN.US)$ +9% (reports top-line results from RECON study of Avance Nerge Graft)
• $积云媒体(CMLS.US)$ +7.2% (an...
暂无评论